In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

Eli Lilly and Company announced detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, ...